Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase

Gene Therapy
F FriedlosC J Springer

Abstract

Clones of human colon carcinoma (WiDr), ovarian carcinoma (SK-OV-3), and Chinese hamster V79 cells expressing the nitroreductase enzyme (NR) from E. coli B were 52-, 225- and 177-fold respectively more sensitive to a 24-h incubation with the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) than the parent lines. The IC50s of non-NR-expressing bystander cells were measured in the presence of differing proportions of NR-expressing cells. The shift in IC50 was used to calculate a value for the bystander effect, termed the transmission efficiency (TE), which is the decrease in IC50 due to bystander effect as a percentage of the maximum decrease possible. The percentage of NR-expressing cells for which the TE was 50%, (the TE50) is a single datum of bystander efficacy. WiDr and V79 cell lines, had a similar TE50 of approximately 2%. SK-OV-3 gave a lower value of 0.3%. These TE50 correlate with concentrations of cytosolic NR activity, which is distinguished from endogenous DT diaphorase activity by kinetic differences. A novel method is described which enables both DNA crosslinks and drug-induced single-strand breaks to be simultaneously quantified in a sedimentation assay. Using this technique, bystander DNA damage was demons...Continue Reading

Citations

Jul 14, 2000·The Journal of Gene Medicine·M AghiX O Breakefield
Mar 10, 2001·Journal of Cellular Physiology·O Greco, G U Dachs
Jun 8, 2001·International Journal of Cancer. Journal International Du Cancer·R A SpoonerR Marais
Dec 21, 2000·Current Oncology Reports·W R Smythe
Oct 8, 1999·Pharmacology & Therapeutics·G M Dubowchik, M A Walker
Oct 8, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·D AndersonL W Seymour
Feb 28, 2002·Breast Cancer Research and Treatment·Wei CuiA John Clark
Aug 10, 2000·The British Journal of Surgery·M ManuS Bramhall
Mar 5, 2002·The Journal of Small Animal Practice·L Blackwood, D J Argyle
May 3, 2000·The Journal of Clinical Investigation·C J Springer, I Niculescu-Duvaz
Nov 4, 2000·Expert Opinion on Investigational Drugs·S R Bramhall
Nov 29, 2015·BioMedicine·Viswanadha Vijaya Padma
Feb 20, 2007·Molecular Aspects of Medicine·Daniel PortsmouthMatthias Renner
Sep 1, 2005·Toxicology·Magdalene Huen Yin TangMalcolm D Tingle
Jun 23, 2015·Journal of the American Chemical Society·William B PorterfieldJennifer A Prescher
Jul 28, 2016·Biochemical Pharmacology·Alexandra M MowdayAdam V Patterson
Jan 18, 2003·International Journal of Cancer. Journal International Du Cancer·Nicola K GreenLawrence S Young
Aug 13, 2002·British Journal of Nursing : BJN·D Child
Mar 17, 2015·Advanced Healthcare Materials·Perry T YinKi-Bum Lee
Apr 21, 2009·Expert Review of Anticancer Therapy·Camilla L ChristensenHans S Poulsen
Feb 17, 2007·Journal of Neuroscience Research·Seung P KwakAfshin Ghavami
Apr 2, 2002·Neoplasia : an International Journal for Oncology Research·Toru ShibataJ Martin Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.